EU/3/16/1676

Table of contents

About

On 27 June 2016, orphan designation (EU/3/16/1676) was granted by the European Commission to Pharma Gateway AB, Sweden, for cyclocreatine for the treatment of creatine deficiency syndromes.

Key facts

Active substance
Cyclocreatine
Disease / condition
Treatment of creatine deficiency syndromes
Date of decision
27/06/2016
Outcome
Positive
Orphan decision number
EU/3/16/1676

Sponsor's contact details

Pharma Gateway AB
Johanneslundsvägen 2
194 61 Upplands Väsby
Sweden
Tel. +46 8 59 07 78 00
Fax +46 8 59 07 14 40
E-mail: info@pharmagateway.eu

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;
  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

How useful was this page?

Add your rating